News Quantified

ALDX – aldeyra therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting

Aldeyra Therapeutics resubmits new drug application for treatment of dry eye disease [Seeking Alpha]

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory [Yahoo! Finance]

5.5%

IN-LINE

-5.3%

MISS

1.7%

MISS

Form 10-Q Aldeyra Therapeutics, For: Sep 30

Form 4 Aldeyra Therapeutics, For: May 03 Filed by: Miller-Rich Nancy

Form 8-K Aldeyra Therapeutics, For: Oct 03

Form 8-K Aldeyra Therapeutics, For: Sep 30

Form 3 Aldeyra Therapeutics, For: Aug 31 Filed by: Alfieri Michael

Top News Gainers

4/14 Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629 27.8%

3/24 Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection 22.9%

9/9 Form 4 Aldeyra Therapeutics, For: Sep 05 Filed by: McMullin David 13.9%

4/27 Form DEF 14A Aldeyra Therapeutics, For: Jun 09 13.1%

10/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%

3/26 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.0%

10/2 Form 4 Aldeyra Therapeutics, For: Sep 30 Filed by: Brady Todd C 8.1%

12/18 Form 4 Aldeyra Therapeutics, For: Dec 16 Filed by: Brady Todd C 5.9%

11/1 Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update 5.0%

1/15 Form 3 Aldeyra Therapeutics, For: Jan 13 Filed by: Miller-Rich Nancy 4.2%

Top News Decliners

12/3 Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease -40.4%

3/24 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. -17.8%

3/17 Form 4 Aldeyra Therapeutics, For: Mar 16 Filed by: DOUGLAS RICHARD -15.3%

3/6 Form 4/A Aldeyra Therapeutics, For: Mar 02 Filed by: Reed Joshua -15.3%

3/12 Aldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones -14.2%

8/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.5%

2/24 Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day -7.3%

2/25 Form SC 13G Aldeyra Therapeutics, Filed by: Prosight Management, LP -7.0%

10/31 Form 8-K Aldeyra Therapeutics, For: Oct 31 -6.7%

4/30 Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First-Quarter 2020 Financial Results and Corporate Update -6.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day